Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
Cabaletta Bio is a clinical-stage biotechnology firm focused on engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio is a clinical-stage biotechnology firm focused on engineered T cell therapies for patients with B cell-mediated autoimmune diseases. On April 14, 2021, at 3:00 p.m. ET, CEO Steven Nichtberger will participate in a fireside chat at the 20th Annual Needham Healthcare Conference. The live webcast will be accessible on the company’s website and will remain available for replay for 90 days. The lead product candidate, DSG3-CAART, targets mucosal pemphigus vulgaris and has received Fast Track Designation from the FDA.
Details
News Market Reaction – CABA
The recorded move for CABA in the trading session of this news was -5.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Healthcare Conference on Wednesday, April 14, 2021 at 3:00 p.m. ET.
A live webcast of the fireside chat will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.